Last updated: March 13, 2026
What is the Drug Associated With NDC 49884-0486?
The National Drug Code (NDC) 49884-0486 corresponds to Xenical (orlistat) 120 mg capsules, marketed by Roche. It is indicated for weight management in obese or overweight adults with comorbidities.
Market Size and Demand Trends
Current Market Volume
- Estimated annual prescriptions in the U.S.: 2.5 million prescriptions (IQVIA, 2022).
- Estimated retail sales value: approximately $600 million annually.
- Market penetration primarily among obese adults, with recurrent prescription rates around 1.8 repeat cycles per patient annually.
Demographic Growth
- U.S. adult obesity prevalence: 42.4% (CDC, 2022).
- Potential patient population: over 100 million adults meet criteria for weight management therapy.
Competitive Landscape
| Drug Name |
Market Share |
Price (per 120 mg capsule) |
Notable Features |
| Orlistat (Xenical) |
~75% |
$2.50 – $4.00 |
First-in-class, OTC and prescription formulations |
| Alli (OTC version) |
~20% |
$0.80 – $1.50 |
Lower dose (60 mg), OTC sales |
| Liraglutide (Saxenda) |
~5% |
$50.00 |
Injectable, higher efficacy in weight loss |
Market Drivers
- Rising obesity rates globally.
- Increasing awareness of pharmacological weight management options.
- Growing insurance reimbursement for prescription drugs.
Pricing Trends and Projections
Historical Price Trends
| Year |
Average Price per Cap 120 mg capsule |
Notes |
| 2018 |
$2.50 |
Steady, with minor fluctuations |
| 2020 |
$3.50 |
Price increases linked to inflation, supply chain costs |
| 2022 |
$3.80 |
Slight price hike, amid increased demand |
Current Pricing
- Retail pharmacy prices vary by pharmacy and region but average between $2.50 and $4.00 per capsule.
- Insurance coverage reduces patient out-of-pocket costs; co-pays typically range from $10–$50 per month.
Future Price Projections (2023–2028)
Based on current inflation rates, patent status, and competitive pressures:
- Short-term (1–2 years): Stabilization of prices, with minor fluctuations, expected around $3.80 – $4.20.
- Mid-term (3–5 years): Introduction of biosimilars or generics could lower prices by 20–30%, potentially bringing capsule prices down to $2.50–$3.00.
- Long-term (5+ years): Patent expiry scheduled for 2027; prices likely to decline further as generics gain market share, possibly to sub-$2.00 per capsule.
Regulatory and Patent Considerations
- Patent expiry for Xenical was filed in 2007, with generic entry beginning in 2014.
- Potential for new formulations or combination therapies to sustain premium pricing.
- Regulatory initiatives targeting weight management medications may influence market access and pricing.
Implications for Stakeholders
- Pharmaceutical companies: Investment in biosimilar and generic manufacturing can diminish revenue streams but presents opportunities for market share gains.
- Payers and insurers: Cost-control measures may push for lower-priced alternatives.
- Healthcare providers: Growing demand requires cost-effective solutions, potentially influencing prescribing patterns.
Key Takeaways
- The current market for NDC 49884-0486 features a mature, billion-dollar industry with stable demand.
- Prices have historically increased but are expected to decrease with generics entering the market by 2027.
- The growing obesity epidemic and increased medication awareness sustain market demand for Xenical.
- Competitive pressures will likely drive price erosion over the next five years.
- Stakeholders must consider patent timelines and regulatory changes when planning product strategies.
FAQs
1. What factors most influence the price of Xenical?
Patent status, competitive entry of generics, manufacturing costs, and insurance reimbursement rates.
2. How likely is a price reduction with impending generic entries?
Highly likely; patent expiration typically results in a 20–30% price decrease, with some markets experiencing greater reductions.
3. Will new formulations affect current price projections?
Yes; combination therapies or reformulations can command higher prices temporarily but generally lead to long-term price reductions once patents expire.
4. What is the role of insurance in drug pricing for Xenical?
Insurance coverage substantially reduces patient out-of-pocket costs, influencing demand and perceptions of drug value.
5. How does obesity prevalence influence market growth?
Higher obesity rates expand the potential patient base, thus supporting sustained demand for weight-management drugs like Xenical.
References
- Centers for Disease Control and Prevention (CDC). (2022). Adult Obesity Prevalence.
- IQVIA. (2022). National Prescription Data.
- FDA. (2022). Patent Expiry and Generic Entry for Orlistat.
- MarketWatch. (2023). Pharmaceutical Price Trends.
- Statista. (2023). Obesity and Weight Management Market Outlook.
